Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335104 | 1.00 | TDP1 (0.51) | TDP1ALDH1A1GAAKMT2AESR1 | |
| SCHEMBL15314537 | 0.83 | TDP1 (0.54) | TDP1ALDH1A1GAAKMT2AESR1 | |
| SCHEMBL9125943 | 0.83 | TDP1 (0.50) | TDP1ALDH1A1GAAKMT2AESR1 | |
| SCHEMBL5936693 | 0.83 | KMT2A (0.38) | TDP1ALDH1A1GAAKMT2ALMNA | |
| SCHEMBL1758062 | 0.81 | TDP1 (0.64) | TDP1ALDH1A1GAAKMT2AESR1 | |
| SCHEMBL8857876 | 0.81 | APOBEC3G (0.46) | ALDH1A1GAAKMT2ALMNAOPRM1 | |
| SCHEMBL27408559 | 0.78 | GAA (0.49) | TDP1ALDH1A1GAAKMT2AESR1 | |
| SCHEMBL9121818 | 0.77 | LMNA (0.51) | GAALMNACYP1A2MAPTPTGS1 | |
| SCHEMBL27966835 | 0.77 | TDP1 (0.66) | TDP1ALDH1A1GAAKMT2AESR1 | |
| Phenol SCHEMBL11032573 | 0.76 | ALDH1A1 (0.41) | TDP1ALDH1A1GAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| EP-1981502-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | Harrogate Holdings (BM) | 2008-10-22 | — | — | EP | claimed |
| WO-2007088489-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | HARROGATE HOLDINGS (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070185145-A1 | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | HARROGATE HOLDINGS (BM) | 2007-08-09 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2024204763-A1 | NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION, DRY FILM, CURED PRODUCT, AND ELECTRONIC COMPONENT | 太陽ホールディングス株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| EP-0032036-B1 | TRIARYLMETHANE DYES, PHOTOGRAPHIC RECORDING MATERIALS, A PROCESS IN WHICH THEY ARE USED, AND METHODS FOR FORMING TRIARYLMETHANE DYES | POLAROID CORPORATION (US) | 1984-03-21 | — | — | EP | disclosed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4304833-A | DIFFUSION TRANSFER | POLAROID CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| EP-0032036-A1 | Triarylmethane dyes, photographic recording materials, a process in which they are used, and methods for forming triarylmethane dyes | POLAROID CORPORATION (US) | 1981-07-15 | — | — | EP | disclosed |
| US-4277407-A | LIGHT-SCREENING AGENTS IN COLOR PHOTOGRAPHY | POLAROID CORPORATION (US) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | TDP1 3469/4885ALDH1A1 2722/4885GAA 98/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | TDP1 1031/4885ALDH1A1 4556/4885GAA 2468/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | TDP1 2090/4885ALDH1A1 1371/4885GAA 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.